Two genome sequencing studies show a consistent association between blood mitochondrial DNA copy number (mtDNAcn) and personality traits and provide support for the hypothesis that mtDNAcn may be a biomarker that connects certain personality characteristics with mortality.

In a prospective, population-based cohort, high polygenic risk and infection with Fusobacterium nucleatum have a small, yet independent impact on coronary heart disease risk.

Mechanistically distinct COX-2 inhibitors reduce stress-induced behavioral pathology via unique multimodal molecular mechanisms, and could be used to treat mood disorders.

This four-DNA methylation signature demonstrates potential as a novel independent prognostic indicator for risk-stratifying patients with CM.

Analysis of proteomic data identified protein biomarkers of aging, mortality and aging-related diseases, supporting their use to monitor aging trajectories and identify individuals at higher risk of disease.

Compared with casirivimab/imdevimab and bamlanivimab/etesevimab, early treatment with sotrovimab seems to reduce the time to sustained recovery among adult outpatients with mild-to-moderate SARS-CoV-2 infection due to Omicron BA.1 and BA.1.1.

Gene copy number provides more prognostic information than gene mutation status in cancer.

A long non-coding RNA removes the transcriptional repressor p50 to regulate recruitment of co-activator p300 and RNA Polymerase II complexes to activate the COX-2 gene in human mammary epithelial cells and macrophages.

Lipoprotein particle size and composition, fatty acids, and amino acids were associated with the risk of incident diabetes, and adding the selected metabolites could significantly improve the risk prediction of progression from prediabetes to diabetes beyond the conventional clinical variables.

AIDPS derived by 76 machine-learning algorithm combinations in 13 independent multicenter cohorts exhibited superior capability than clinical traits and 86 published prognostic signatures and could serve as an ideal biomarker for stratified management and individualized treatment of pancreatic cancer.